Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(near death experience)
824,030 results
  • The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. [Journal Article]
    Nature 2019Bersuker K, Hendricks J, … Olzmann JA
  • Ferroptosis is a form of regulated cell death that is caused by the iron-dependent peroxidation of lipids1,2. The glutathione-dependent lipid hydroperoxidase glutathione peroxidase 4 (GPX4) prevents ferroptosis by converting lipid hydroperoxides into non-toxic lipid alcohols3,4. Ferroptosis has been implicated in the cell death that underlies several degenerative conditions2, and induction of fer…
  • FSP1 is a glutathione-independent ferroptosis suppressor. [Journal Article]
    Nature 2019Doll S, Freitas FP, … Conrad M
  • Ferroptosis is an iron-dependent form of necrotic cell death marked by oxidative damage to phospholipids1,2. To date, ferroptosis has been believed to be restrained only by the phospholipid hydroperoxide (PLOOH)-reducing enzyme glutathione peroxidase 4 (GPX4)3,4 and radical-trapping antioxidants (RTAs)5,6. The factors which underlie a given cell type's sensitivity to ferroptosis7 are, however, cr…
  • Biological effects and activity optimization of small-molecule, drug-like synthetic anion transporters. [Review]
    Eur J Med Chem 2019; 184:111782Yu XH, Hong XQ, … Chen WH
  • The balance of normal anion concentrations in cells provides basis for maintaining cellular morphology and function. Disrupting the homeostasis of cellular anions and lysosomal pH, in particular with high selectivity for cancer cells over normal cells may serve as a promising approach for the treatment of cancers. Small-molecule organic compounds with transmembrane anion transport activity, namel…
  • Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? [Review]
    Eur J Cancer 2019; 122:72-90Michot JM, Lazarovici J, … Lambotte O
  • Immune checkpoint inhibitors (ICIs) are changing the treatments of many patients with cancer. These immunotherapies are generally better tolerated than chemotherapy, and their adverse events are immune-related mimicking autoimmune or inflammatory conditions. Although these immune-related adverse events mainly affect the skin, endocrine glands, digestive tract, joints, liver or lungs, all the orga…
New Search Next